PREVALENCE OF CLOPIDOGREL RESISTANCE AND GENETIC PROFILE AMONG A GROUP OF PCI PATIENTS IN DUHOK CITY

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Clopidogrel is a vital antiplatelet medication used post-percutaneous coronary intervention (PCI) for coronary heart disease (CAD).
• Patient response to clopidogrel varies, with clopidogrel resistance posing a clinical challenge requiring further investigation.

Purpose of the Study:

• To evaluate the prevalence of clopidogrel resistance in patients who have undergone PCI.
• To explore potential correlations between clopidogrel resistance and patient demographics such as age and gender.

Main Methods:

• A cross-sectional study involving 106 patients who underwent primary PCI and received clopidogrel for at least 7 days.
• Platelet aggregation tests were performed on blood samples to assess patient response to clopidogrel.
• Genetic analysis was conducted on patients identified with clopidogrel resistance.

Main Results:

• 17.1% of patients exhibited clopidogrel resistance, while 70.5% responded positively and 12.4% showed a suboptimal response.
• No statistically significant correlation was observed between clopidogrel response and patient age (P=0.4159) or gender (P=0.2324).
• Genetic analysis of resistant cases also showed no significant correlation with age (P=0.8914) or gender (P=0.2524).

Conclusions:

• Clopidogrel resistance is a notable clinical issue in patients post-PCI.
• Current findings suggest that age and gender do not significantly influence clopidogrel resistance.
• Further research into the genetic factors influencing clopidogrel response is warranted.